Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12.

Thomas A Hope^{1

2}, Emily K Bergsland^{3

4}, Murat Fani Bozkurt⁵, Michael Graham⁶, Anthony P Heaney⁷, Ken Herrmann⁵, James R Howe^{4

8}, Matthew H Kulke^{3

4

9}, Pamela L Kunz^{3

4

9}, Josh Mailman¹⁰, Lawrence May¹¹, David C Metz^{4

12}, Corina Millo⁶, Sue O'Dorisio^{6

3

4}, Diane L Reidy-Lagunes^{3

4}, Michael C Soulen^{4

13}, Jonathan R Strosberg^{3

4}

¹ Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia thomas.hope@ucsf.edu.
² American College of Radiology, Reston, Virginia.
³ American Society of Clinical Oncology, Alexandria, Virginia.
⁴ North American Neuroendocrine Tumor Society, Albany, New York.
⁵ European Association of Nuclear Medicine, Vienna, Austria.
⁶ Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia.
⁷ Endocrine Society, Washington, DC.
⁸ Society of Surgical Oncology, Rosemont, Illinois.
⁹ National Comprehensive Cancer Network, Fort Washington, Pennsylvania.
¹⁰ NorCal CarciNET, Ripon, California.
¹¹ American College of Physicians, Washington, DC.
¹² American Gastroenterological Association, Bethesda, Maryland; and.
¹³ Society of Interventional Oncology, Washington, DC.

No abstract available

MeSH terms